2023-507654-33-00RecruitingPhase 1/2
MB-CART19.1 in refractory SLE
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Sept 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 4 Oct 2023
- Start date
- 12 Aug 2024
- Lead sponsor
- Miltenyi Biomedicine GmbH
- Diseases
- Lupus (SLE)
- EU CT number
- 2023-507654-33-00
- EudraCT number
- 2022-003137-19
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 30
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitaetsklinikum Erlangen AöR | Erlangen | Germany | Recruiting |
| Otto Von Guericke Universitaet Magdeburg | Magdeburg | Germany | Recruiting |
| Universitaetsklinikum Tuebingen AöR | Tuebingen | Germany | Recruiting |
| Universitaetsklinikum Wuerzburg AöR | Wuerzburg | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.